Have you or your loved ones been diagnosed with lyme arthritis?

You may be eligible to participate in a lyme arthritis clinical trial.

Have you or your loved ones been diagnosed with lyme arthritis? You may be eligible to participate in a lyme arthritis clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Lyme Arthritis Clinical Trial in Pittsburgh PA
NCT04038346 | Phase 3 | Interventional
Desiree Neville MD
Sponsored by
Desiree Neville MD

Have you or your loved ones been diagnosed with lyme arthritis?

You may be eligible to participate in a lyme arthritis clinical trial.

Have you or your loved ones been diagnosed with lyme arthritis? You may be eligible to participate in a lyme arthritis clinical trial.

Recruiting

Male & Female

3 - 17

Years old

This study is looking to recruit 300 Participants

Lyme arthritis resolves with appropriate antimicrobial treatment in a majority of patients, but 10-20% of patients develop antibiotic-refractory Lyme arthritis with prolonged arthritis symptoms and treatment courses. Excessive up-regulation of the inflammatory process has been shown in patients with antibiotic-refractory Lyme arthritis. The over-expressed pro-inflammatory cell mediators are downstream of NSAID inhibition, which would suggest initial inflammatory inhibition may be beneficial in these patients. While NSAIDs are known to reduce pro-inflammatory cell mediators early in the course of inflammation, research has shown that there are other cytokines that play a role in the healing after inflammation that are also inhibited by NSAIDs, and that NSAID use can delay healing. It is not known if scheduled NSAID therapy will reduce, increase, or have no effect on the occurrence of refractory Lyme arthritis cases. The hypothesis of the study is that prescribing scheduled NSAIDs at the time of diagnosis of Lyme arthritis can prevent the development of the excessive inflammatory phase and decrease the number of patients with antibiotic-refractory Lyme arthritis, or at least decrease the duration of persistent Lyme arthritis symptoms. The pilot study design randomizes patients to scheduled NSAIDs, scheduled acetaminophen, or scheduled NSAIDs x 1 week than acetaminophen. Primary outcomes are duration of arthritis symptoms, number of refractory cases, side effects and compliance.